Study S002002

A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apitegromab in Overweight and Obese Adult Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06445075
Acronym: EMBRAZE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 102
Start: 2024-05-21
Primary completion: 2025-03-04
Lead sponsor: Scholar Rock, Inc.
Conditions: Overweight and Obesity
Interventions: DRUG:Apitegromab; DRUG:Placebo; DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Change from Baseline in total Lean Body Mass (kg) at 24 weeks [Baseline and 24 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009133	Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Pratley RE, Nature medicine	2026	Randomized trial	PMID 42260100 DOI	cites ClinicalTrials.gov:NCT06445075; registry reference DERIVED:42260100